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Understanding the neurobiology underlying dementias is of paramount importance as finding ways to 
prevent or treat these diseases is one of the biggest medical challenges of our time. Dementia 
symptoms in people over 65 are most commonly associated with Alzheimer’s disease (AD) 
pathologies - brain atrophy and the accumulation of amyloid-beta (Aβ) and tau aggregates.  A report 
recently published in Brain draws attention to another pathological association with dementia in people 
over 80 that they named “Limbic-predominant age-related TDP-43 encephalopathy” (or LATE) (Nelson 
et al., 2019). 
The accumulation of TDP-43 (transactive response DNA-binding protein 43 kDa) pathology in the 
brain during ageing and in association with dementia and other neurodegenerative diseases is not a 
new observation (Spires-Jones, Attems, & Thal, 2017; Wyss-Coray, 2016). However this new paper 
based on a working group of international scientists is important as it highlights that amnestic 
dementia in late life is often mis-diagnosed as AD, when the neuropathologic changes are instead 
those they describe for LATE (LATE-NC). The clinical presentation is similar to AD, while the 
pathological features are TDP-43 aggregates similar to those seen in amyotrophic lateral sclerosis 
(ALS) and the frontotemporal dementia (FTD) cases that have TDP-43 pathology, albeit with distinct 
spatial and temporal accumulations from ALS/FTD (Nelson et al., 2019).  
TDP-43 proteinopathy was first identified in 2006 in both ALS and FTD (Cairns et al., 2007; Neumann 
et al., 2006).  Later it was found in cases of AD and reported to modify the clinical phenotype (Josephs 
et al., 2008), and it is now recognised to be a prevalent mis-folded protein both in cognitively normal 
ageing and neurodegenerative diseases, and is associated with cognitive decline in the ‘oldest-old’ 
(Wyss-Coray, 2016). In this report, Nelson and colleagues summarize data from large community-
based studies  and observe LATE-NC in ˃20% of cases over the age of 80. Genetic risk factors of 
LATE overlap both with FTLD-TDP and AD, and LATE is thought to be 100 times more prevalent than 
FTD syndromes. Based on these data, authors suggest that the public health impact of LATE may be 
on the same order of magnetide as AD (Nelson et al., 2019).  
The authors propose a neuropathological stageing scheme for LATE with pathology in stage 1 in 
amygdala, stage 2 spreading to hippocampus, and stage 3 spreading to middle frontal gyrus (Nelson 
et al., 2019).  Further, this report offers diagnostic approaches to differentiate LATE-NC from FTD and 
AD. Behavioural and aphasic syndromes are more typical of FTLD-TDP and amnestic syndrome more 
typical of LATE-NC. Compared to AD, LATE has later onset of symptoms, more restricted involvement 
of limbic structures and presence of hippocampal sclerosis (HS), which is often unilateral (Amador-
Ortiz et al., 2007).  Subjects with impaired word list delayed recall (hippocampal-dependent) and 
relatively preserved verbal-fluency (neocortical-dependent) will be expected to show predominantly 
LATE-NC post-mortem (Nelson et al., 2011). Also, when PET scans for tau and amyloid do not 
correlate with the clinical severity in a patient with episodic memory loss and prominent HS, these 
findings will be suggestive of LATE.  
So what is the importance of this paper with regard to clinical practice? By highlighting a relatively 
common and previously under-reported pathology, and putting this pathology clearly within a clinical 
framework, the authors have reminded the dementia research community of the fundamental need to 
understand what they are trying to treat. By assuming all amnestic syndromes in older patients are 
AD, researchers are missing potentially confounding co-pathologies and may actually be missing the 
key pathologic driver of cognitive decline, and therefore missing the key molecular pathway for 
intervention. Introducing a post-mortem confirmation of the key pathologies associated with cognitive 
decline for at least a proportion of clinical cohorts would go someway to providing an assessment of 
the cohort being studied, rather than assuming the key pathology based on clinical presentation. The 
neuropathology community has developed detailed grading systems to standardise assesment of a 
number of pathologies such as p-tau, Aβ, -synuclein, and cerebrovascular pathology, and this 
publication standardises the approach to TDP-43 assessment.  
This report stresses the fact that although AD remains by far the most common cause of dementia, the 
clinician should also think of LATE, especially when the onset of symptoms are in advanced age. It will 
be interesting to see how our understanding of this condition will evolve over time and how the 
dementia research community will modify their approach to clinical trials to take account of this 
important confounding degenerative pathology in later life.  
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